Abstract 1658 Use of a red fluorescent small molecule for real-time tracking of cyclic di-nucleotide production and degradation by c-di-AMP cyclase and phosphodiesterase enzymes

Tuberculosis is one of the oldest and deadliest diseases in the world. Although treatable, the emergence of multidrug-resistant tuberculosis is rendering current drug treatments ine9ective. Thus, the development of new medicines is necessary to help those in need. The c-di-AMP phosphodiesterase CdnP (also called NrnA) has been identified as a new drug target. The cleaving of c-di-AMP by CdnP decreases the recognition of the cyclic dinucleotides by the host, impeding the host's immune response to tuberculosis.